publication venue for
- 6P Organoid models reveal endometrial cancer microenvironment and drug resistance. 10:105135. 2025
- 95O Atezolizumab plus ipatasertib shows promise in extending survival for patients with PI3K/AKT/PTEN-altered advanced solid tumors: An exploratory analysis of the ROME trial. 10:104256. 2025
- 126P A randomized controlled trial (RCT) comparing optimal local treatment with or without endocrine therapy (ET) in patients (pts) aged ≥70 with lower risk breast cancer (BC) [REaCT-70 Study]. 9:103114-103114. 2024
- 297P Modified Delphi consensus on interventions for radiation dermatitis in breast cancer: A Canadian expert perspective. 9:103354. 2024
- 44O Updated results from a phase I study evaluating the KRAS G12C inhibitor MK-1084 in solid tumors and in combination with pembrolizumab in NSCLC. 9:102273-102273. 2024
- 164P Adjuvant radiation therapy amongst immigrant and Canadian-born/long-term resident women with breast cancer. 8:101504-101504. 2023
- 70MO Genomic profiling to expand precision cancer medicine in the real world: The ROME trial. 8:100928-100928. 2023
- Corrigendum to ‘Towards a novel approach guiding the decision-making process for anticancer treatment in patients with advanced cancer: framework for systemic anticancer treatment with palliative intent’. 7:100614-100614. 2022
- Reporting of tobacco use and tobacco-related analyses in cancer cooperative group clinical trials: a systematic scoping review. 7:100605-100605. 2022
- Corrigendum to ‘COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC)’. 6:100243-100243. 2021
- COVID-19 epidemic strongly affected cancer research in Italy: a survey of the Italian Cancer Society (SIC). 6:100165-100165. 2021
- Cancer cachexia in adult patients: ESMO Clinical Practice Guidelines☆. 6:100092-100092. 2021
- Cediranib in addition to chemotherapy for women with relapsed platinum-sensitive ovarian cancer (ICON6): overall survival results of a phase III randomised trial. 6:100043-100043. 2021
- Examining policy cohesion for cervical cancer worldwide: analysis of WHO country reports. 5:e000878-e000878. 2020
- Patient and family support in the era of fake e-medicine: food for thought from an international consensus panel. 5:e000696-e000696. 2020
- Contrasting evidence to reimbursement reality for off-label use (OLU) of drug treatments in cancer care: rationale and design of the CEIT-OLU project. 4:e000596-e000596. 2019
- Prognostic indices of inflammatory markers, cognitive function and fatigue for survival in patients with localised colorectal cancer. 3:e000302-e000302. 2018
- Back to the ‘essence’ of medical treatment in oncology: the 2015 WHO Model List of Essential Medicines. 1:e000030-e000030. 2016
- Comparing assessment frameworks for cancer drugs between Canada and Europe: What can we learn from the differences?. 1:e000124-e000124. 2016